DoW Peer Reviewed Medical, Clinical Trial Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The fiscal year 2026 Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award, solicitation HT942526PRMRPCTA, is a federal assistance opportunity issued by the Defense Health Agency to support clinical trials that improve the treatment and management of diseases within congressionally directed topic areas. The program supports two application categories: Clinical Trial Only and Clinical Trial with Planning Phase. The planning phase is limited to 12 months and a cost cap of $800,000 to finalize regulatory activities, while the clinical trial phase has a maximum performance period of 4 years. Funding is divided into three levels based on the trial phase and participant count: Level 1 for phase 0/1 or fewer than 100 participants (up to $6M), Level 2 for phase 2 or fewer than 300 participants (up to $10M), and Level 3 for phase 3 or more than 300 participants (up to $20M). The Department of Defense expects to allot approximately $94.5M to fund about 9 applications. Applicants must be registered in SAM.gov, eBRAP.org, and Grants.gov, with a full application deadline of September 22, 2026. The evaluation process consists of a two-tier review focusing on technical merit through peer review and programmatic relevance through a second review, with specific emphasis on the impact on Service Members, Veterans, and their families. Key requirements include a detailed study population recruitment and safety plan, a regulatory strategy for FDA approvals, and a signed sponsor commitment letter. All preclinical empirical laboratory work must be completed prior to the award start date, and animal studies are not supported. Awardees are required to submit quarterly, annual, and final technical progress reports via the Research Performance Progress Report.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.
Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date.
Supports three funding levels, each offered with and without a Planning Phase:
Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants.
Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants.
Funding Level 3: Supports phase 3 clinical trials or non-phased trials with more than 300 participants.
Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $94.5M to fund approximately 9 Clinical Trial Award applications with total cost caps of $800,000 for the planning phase of a Clinical Trial with Planning Phase, $6M for Funding Level 1, $10M for Funding Level 2, and $20M for Funding Level 3 per award. The maximum period of performance is 4 years for the clinical trial, and 12 months for the planning phase. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Department Of The Army -- Usamraa
Same awarding agency